Evidence Hub

Thrombolytic Therapy for Massive Pulmonary Embolism in an Antiphospholipid Syndrome Patient With Severe Thrombocytopenia: A Case Report

A. Ahmadzadeh, Samad Nazar Poor, Reza Hamneshin Behbahani, Pegah Soltani, A. Tavasol, Mehdi Sheibani

Clinical Case Reports, 2025

2 citations

Abstract

Thrombocytopenia (TCP) is a well‐known contraindication for thrombolytic therapy due to the associated risk of bleeding. This report discusses a 34‐year‐old woman presented with massive pulmonary embolism (PE) and severe TCP. She was treated with systemic thrombolysis (ST), and fortunately, a good therapeutic response was achieved without significant bleeding. Further evaluations confirmed the diagnosis of antiphospholipid syndrome for the patient. This case highlights that ST can be a viable therapeutic option for managing massive PE in thrombocytopenic patients under specific circumstances, warranting further research into its safety and efficacy.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free